OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Pharmaceutical Technology Europe
Paul Gardiner and Andrea Sobrio explain why most companies need 'organizational polygamy' to maximize profit and best serve their customers.
Traditionally, pharmaceutical organizations consist of small global and regional organizations and large, autonomous affiliate organizations. While this can be the best model, for many products, therapeutic areas or business units, it is less effective and more costly than centralized structures. Also, with the emergence of new technological innovations, particularly in connectivity and communication, the relevance of country borders as the main drivers of clinical decision making is diminishing considerably.
For our purposes, the three organizational models are:
In the traditional affiliate model, the majority of headcounts and budget is allocated to the affiliates. This model is geared to offering services highly customized to local needs, and is very effective in covering large local general practitioner (GP) communities. However, this will always be the highestcost option because of the inefficiencies inherent in replicating efforts and organizational structures in each country. Effectiveness is hampered by suboptimal dissemination of scientific knowledge, nonaligned messages across geographies and different approaches to identifying and managing key opinion leaders.
The hybrid model sees strong regional marketing and medical teams working closely with local brand teams. Affiliate activities are reduced to localization and local implementation.
The global/regional model has all commercial operations personnel reporting into a single centralized organization with profit and loss responsibility. A regional backoffice support group (HR, finance, etc.) supports the global/regional organization.
Table 1 indicates the impact of the different organizations on key functions.
Table 1: The impact of different organizations on key functions.
There are two factors that need to be considered when deciding on the optimal organizational models for products/portfolio(s)/therapeutic areas. The first is the complexity of the products (mode of action and administration) and the therapeutic area (diagnosis and treatment). Highly specialized customer groups, working with complex therapeutic areas and products, have specific needs, such as:
The second factor is the size of the customer base, which requires the following to be considered:
Figure 1 combines the two factors discussed above.
In small or focused companies, all products/therapeutic areas can fit into the same quadrant. However, for mid-size and larger companies, 'organizational polygamy' is probably the best option.
Let's look at a hypothetical scenario. ACME Pharmaceuticals had a traditional affiliate structure with the big five EU general managers, and the cluster leaders of mid-size and eastern EU countries, reporting into the European operations president.
However, ACME's customer equity surveys were showing an alarming trend. While GPs were very happy with their interactions with ACME, specialist customer groups were far less content, with oncology and intensive care performing worst.
Based on competitor research and a thorough business review, the EU operations president prepared a proposed new EU organizational structure to share with his leadership team. He titled his presentation 'Organizational Polygamy: Why having three models is better than one'
His proposed structure had three components:
The European leadership team accepted the proposal, and the transformation programme was launched. After 3 months of design, and 6 months of preparation, the polygamous organization was successfully launched.
The polygamous organization's metrics continuously improved after launch. Three years after the launch, the European operations president presented organizational improvement metrics. The company chairman was particularly interested in the following metrics for oncology and intensive care combined:
Despite this decrease in headcount, the intensive care and oncology business units experienced unprecedented improvements in customer equity.
Europe comprises more than 20 countries, each with their own approval, regulatory and legal processes. This diverse yet fast converging domain is ideal for centralized or panEuropean organizations, allowing the EU to become a showcase for the rest of the world.
However, while this is a successful trend in Europe, some organizations have tried polygamy, only to fail and revert to their monogamous ways. Identifying and exploiting the benefits, whilst avoiding the pitfalls, will be critical to your success.
We've seen in the past and present how organization models are often fashions that come and go. However, like it or not, organizational polygamy is a clear trend that will continue, and that if managed correctly, can provide a much needed boost to your brand(s). Is it time for your organization to start behaving in a polygamous manner?
About the authors
Paul Gardiner is an associate, and Andrea Sobrio is a partner, at Executive Insight, a professional services firm focusing on the healthcare industry.